# Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

> **NCT01117818** · PHASE2 · COMPLETED · sponsor: **Affiris AG** · enrollment: 335 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** active: AFFITOPE AD02
- **BIOLOGICAL:** control: Placebo

## Key facts

- **NCT ID:** NCT01117818
- **Lead sponsor:** Affiris AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2013-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01117818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01117818, "Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01117818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*